NCT00000813View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 1995

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV gp160MN (vCP125)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (1)

Unknown

JHU AVEG, Baltimore

All Listed Sponsors
collaborator

Pasteur Merieux Connaught

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000813 - A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers | Biotech Hunter | Biotech Hunter